ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

MUNICH, August 30, 2016 /PRNewswire/ --

Not for US or UK media

- ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral
anticoagulant in patients with non-valvular atrial fibrillation - who undergo
electrical cardioversion 
- ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded Endpoint evaluation (PROBE)
, parallel-group phase 3b study, evaluating the efficacy and safety of once-daily
edoxaban versus enoxaparin/warfarin in patients undergoing electrical cardioversion 
- The results demonstrate that LIXIANA may be an effective and safe alternative to
conventional treatment with enoxaparin and a vitamin K antagonist (VKA), and may allow
prompt cardioversion to be performed with transoesophageal echocardiography (TEE)  
- Results from the ENSURE-AF study were presented during ESC Congress 2016 Hot Line
session and the full results are published in The Lancet 

Daiichi Sankyo Europe GmbH Group (hereafter "Daiichi Sankyo") today announced results from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm). The study demonstrated that oral, once-daily edoxaban (known by the brand name LIXIANA(R) outside the US and SAVAYSA(R) in the US) met the study's primary endpoints, demonstrating comparable efficacy and safety to well-managed enoxaparin/warfarin (mean time in therapeutic range on warfarin was 70.8%) for the prevention of stroke and other blood clot complications.[1] Results from ENSURE-AF were presented today during a Hot Line session and late-breaking oral presentation at ESC Congress 2016 in Rome, and published online in The Lancet.

"The results of ENSURE-AF show that once-daily edoxaban may be a viable treatment option for NVAF patients undergoing cardioversion, as demonstrated by the largest prospective dataset for a non-vitamin K antagonist oral anticoagulant in this clinical setting to date," said Andreas Goette, MD, Chief Physician, St. Vincenz-Hospital Paderborn, Germany, Department of Cardiology and Intensive Care Medicine and principal study investigator. "These results may have important clinical implications for newly diagnosed non-anticoagulated AF patients undergoing cardioversion. According to the study protocol, a newly diagnosed non-anticoagulated AF patient was started on edoxaban, and the cardioversion procedure was scheduled as early as two hours following the start of treatment when applying a TEE-guided approach."

ENSURE-AF is a PROBE parallel group study designed to evaluate the efficacy and safety of once-daily edoxaban versus enoxaparin/well-managed warfarin in patients with NVAF undergoing electrical cardioversion. For the primary efficacy outcome evaluating the composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular mortality, edoxaban demonstrated a similar incidence compared to enoxaparin/warfarin (0.5% vs. 1.0%, respectively) (odds ratio [OR], 0.46; 95% confidence interval [CI], 0.12 to 1.43). The main difference between the treatment groups was driven by cardiovascular mortality, with one event in the edoxaban group and five events in the enoxaparin/warfarin group (0.1% vs. 0.5%, respectively).[1],[2]

For the combined principal safety outcome of the incidence of major and clinically-relevant non-major (CRNM) bleeding, events occurred in 1.5% of patients in the edoxaban group and 1.0% in the enoxaparin/warfarin group (OR, 1.48; 95% CI, 0.64 to 3.55). The difference was statistically non-significant. The incidence of major bleeding was numerically lower in the edoxaban group compared to the enoxaparin/warfarin group (0.3% vs. 0.5%, respectively) (OR: 0.61; 95% CI, 0.09 to 3.13). No intracranial bleedings were reported in the study in either of the treatment groups. No fatal bleeding was reported in the edoxaban group vs. one patient in the enoxaparin/warfarin group.[1],[2]

The result for the net clinical outcome (composite of stroke, systemic embolic event, myocardial infarction, cardiovascular mortality, and major bleeding) was 0.7% in the edoxaban group and 1.4% in the enoxaparin/warfarin group (OR=0.50; 95% CI, 0.19 to 1.25) during the overall study period.[1],[2]

Of note, the trial was not adequately powered to demonstrate statistical differences for efficacy or safety endpoints, but provides further insights on the use of edoxaban in the setting of electrical cardioversion of NVAF.[1],[2]

In the ENSURE-AF study, patients were stratified according to cardioversion approach (TEE or non-TEE), a patient's prior experience taking anticoagulants at the time of randomization (i.e. anticoagulant-experienced or naïve), and edoxaban dose (60 mg once-daily or reduced 30 mg once-daily). Patients were randomized in a 1:1 ratio to two treatment groups within each stratum. Edoxaban was dosed at 60 mg once-daily. The dose was reduced to edoxaban 30 mg once-daily for those patients if one or more factors (renal impairment, low body weight, or concomitant use of certain P-glycoprotein inhibitors) were present. Patients in the enoxaparin/warfarin group received optimized standard of care such that those with International Normalized Ratio (INR)

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234